Press Release

Press Inquiries Contact
ICR
Revance@icrinc.com

10

November

2021

Revance to Participate in the Stifel 2021 Virtual Healthcare Conference

09

November

2021

Revance Reports Third Quarter 2021 Financial Results, Provides Corporate Update

02

November

2021

Revance to Release Third Quarter 2021 Financial Results on Tuesday, November 9, 2021

15

October

2021

Revance Provides Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines

12

October

2021

Revance Continues to Anticipate FDA Approval of DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines in 2021

11

October

2021

Revance Announces the Launch of OPUL™, the First-of-its-Kind Relational Commerce Platform for Aesthetic Practices